<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054609</url>
  </required_header>
  <id_info>
    <org_study_id>18-6114</org_study_id>
    <nct_id>NCT04054609</nct_id>
  </id_info>
  <brief_title>FAZA PET/MRI in CLI Patients Pre and Post Revascularization</brief_title>
  <official_title>Evaluation Of Prognostic Value of 18f-Fluoroazomycin Arabinoside (FAZA) Positron Emission Tomography/Magnetic Resonance Imaging (PET/MR) In Patients With Critical Limb Ischemia Pre- and Post Revascularization: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral artery disease is a worldwide problem, leading to high mortality and mobility.&#xD;
&#xD;
      Critical limb ischemia (CLI) is associated with high risk of amputation with the subsequent&#xD;
      decreased in life quality. Endovascular therapy is now considered the primary treatment&#xD;
      option in these patients to improve the vascularity and prevent amputations.&#xD;
&#xD;
      In recent years, development of molecular imaging tools are now become available. A recent&#xD;
      radio tracer named 18F-Fluoroazomycin Arabinoside (FAZA) its an specific marker of hypoxia in&#xD;
      the tissues and has been used in multiples studies. This tracer can be used in PET/MR scan&#xD;
      providing a potentially power diagnostic tool in patients with CLI, allowing in one&#xD;
      diagnostic study the evaluation of location and degree of hypoxia in the extremity tissues.&#xD;
      This diagnostic tool may offer a better assessment pre and post standard of care endovascular&#xD;
      treatment for the patients.&#xD;
&#xD;
      Moreover, some of the patients treated with endovascular therapy may not have a favorable&#xD;
      outcome, without a clear reason explaining this situation. We will try to find some predictor&#xD;
      model in the FAZA PET/MR that can explain the different outcomes and may help clinicians&#xD;
      choose the best treatment option in specific cases.&#xD;
&#xD;
      Thirdly, post processing for optimization of the MR sequences in patients with CLI will be&#xD;
      performed at the MR component of the PET. There would thus be great clinical interest in&#xD;
      developing non-invasive tools that could provide more accurate diagnostic information&#xD;
      compared to traditional tests for these patients population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>FAZA PET/MRI scan pre and post standard of care endovascular treatment for critical limb ischemia patients</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of FAZA PET/MRI as a biomarker of hypoxia</measure>
    <time_frame>FAZA PET/MRI 2-3 weeks before endovascular treatment and 4-6 weeks after endovascular treatment</time_frame>
    <description>The change of degree and pattern of 18F-Fluoroazomycin Arabinoside (FAZA) uptake in the PET/MRI scan of limb in patients with critical limb ischemia</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>FAZA PET/MRI scan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PET/MRI scan using radiotracer 18F-Fluoroazomycin Arabinoside</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FAZA PET/MRI scan</intervention_name>
    <description>PET/MRI scan using radio tracer named 18F-Fluoroazomycin Arabinoside (FAZA) pre and post standard of care endovascular treatment for critical limb ischemia patients</description>
    <arm_group_label>FAZA PET/MRI scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years;&#xD;
&#xD;
          -  Patients with clinical evidence of critical limb ischemia that are candidates for&#xD;
             revascularization treatment;&#xD;
&#xD;
          -  A negative urine or serum pregnancy test in women of child-bearing age;&#xD;
&#xD;
          -  Ability to provide written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication for MR as per current institutional guidelines;&#xD;
&#xD;
          -  Inability to lie supine for at least 30 minutes;&#xD;
&#xD;
          -  Pregnant or breastfeeding;&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent;&#xD;
&#xD;
          -  Impending amputation within 6 weeks of presentation;&#xD;
&#xD;
          -  Previous metallic hardware in the lower limbs;&#xD;
&#xD;
          -  Unable to have ethanol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Veit-Haibach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Veit-Haibach, MD</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>6085</phone_ext>
    <email>Patrick.Veit-Haibach@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

